Zinc Finger CCCH-type, RNA Binding Motif and Serine/arginine-rich 2 (ZRSR2) Gene Mutation Analysis
The ZRSR2 gene at Xp22.2 codes for a splicing factor required for pre-RNA splicing. Pre-RNA splicing is an important post-transcriptional modification that involves the removal of introns via spliceosomes. Different spliceosomes are involved in pre-RNA splicing and the splicing factor synthesized via the ZRSR2 gene comprises an essential component of the U12 spliceosome. Mutations in the ZRSR2 gene have been linked to poor RNA splicing and are associated with the development of myeloproliferative neoplasms. ZRSR2 mutations have been observed most frequently in myelodysplastic syndromes (MDS), CMML, and AML. Approximately 2-3% of MDS cases have ZRSR2 mutations particularly therapy related MDS (8.5%). Similarly, in 2% and 1% of CMML and AML cases respectively, harbor ZRSR2 mutations.
- As an aid in the diagnosis of MDS, CMML, and AML
- Disease management and prognosis
Negative for mutations analysis (no mutations or pathogenic variants detected)
Whole blood, ACD (Yellow-top), or EDTA (Lavender-top).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Medicine (Baltimore). 2019 May;98(21):e15743. [PMID: 31124956]
- Blood. 2012 Apr 12;119(15):3578-84. [PMID: 22389253]
- Anticancer Res. 2015 May;35(5):3081-9. [PMID: 25964599]
- BMC Cancer. 2015 Jun 27;15:484. [PMID: 26115659]